PT MILLENNIUM PHARMACON INTERNATIONAL TBK |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 126 IDR | -0.79% |
|
-5.97% | -20.25% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 121,030 | 121,030 | 132,496 | 173,264 | 422,968 | 201,292 |
| Enterprise Value (EV) 1 | 544,518 | 584,227 | 536,463 | 603,032 | 1,019,601 | 900,285 |
| P/E ratio | 6.22 x | 15.4 x | 47.2 x | 18.1 x | 17.3 x | 6.08 x |
| Yield | 3.16% | 1.05% | 0.48% | 0.74% | 0.6% | - |
| Capitalization / Revenue | 0.05 x | 0.04 x | 0.05 x | 0.06 x | 0.13 x | 0.06 x |
| EV / Revenue | 0.23 x | 0.21 x | 0.2 x | 0.2 x | 0.32 x | 0.27 x |
| EV / EBITDA | 8.08 x | 8.29 x | 9 x | 9.47 x | 12.8 x | 9.71 x |
| EV / FCF | -4.02 x | -24.8 x | 5.57 x | -104 x | -8.33 x | -14.5 x |
| FCF Yield | -24.9% | -4.03% | 17.9% | -0.96% | -12% | -6.87% |
| Price to Book | 0.52 x | 0.51 x | 0.58 x | 0.73 x | 1.63 x | 0.72 x |
| Nbr of stocks (in thousands) | 1,274,000 | 1,274,000 | 1,274,000 | 1,274,000 | 1,274,000 | 1,274,000 |
| Reference price 2 | 95.00 | 95.00 | 104.0 | 136.0 | 332.0 | 158.0 |
| Announcement Date | 18/03/19 | 30/03/20 | 31/05/21 | 31/03/22 | 04/04/23 | 28/03/24 |
1IDR in Million2IDR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 2,376,183 | 2,726,755 | 2,643,627 | 2,988,849 | 3,200,833 | 3,363,518 |
| EBITDA 1 | 67,354 | 70,466 | 59,617 | 63,699 | 79,868 | 92,723 |
| EBIT 1 | 62,698 | 64,604 | 52,771 | 57,475 | 73,900 | 92,717 |
| Operating Margin | 2.64% | 2.37% | 2% | 1.92% | 2.31% | 2.76% |
| Earnings before Tax (EBT) 1 | 28,591 | 11,969 | 7,739 | 17,923 | 36,464 | 47,961 |
| Net income 1 | 19,444 | 7,880 | 2,804 | 9,571 | 24,464 | 33,088 |
| Net margin | 0.82% | 0.29% | 0.11% | 0.32% | 0.76% | 0.98% |
| EPS 2 | 15.26 | 6.185 | 2.201 | 7.513 | 19.20 | 25.97 |
| Free Cash Flow 1 | -135,391 | -23,544 | 96,277 | -5,814 | -122,356 | -61,877 |
| FCF margin | -5.7% | -0.86% | 3.64% | -0.19% | -3.82% | -1.84% |
| FCF Conversion (EBITDA) | - | - | 161.49% | - | - | - |
| FCF Conversion (Net income) | - | - | 3,433.14% | - | - | - |
| Dividend per Share 2 | 3.000 | 1.000 | 0.5000 | 1.000 | 2.000 | - |
| Announcement Date | 18/03/19 | 30/03/20 | 31/05/21 | 31/03/22 | 04/04/23 | 28/03/24 |
1IDR in Million2IDR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 423,488 | 463,197 | 403,967 | 429,768 | 596,633 | 698,993 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 6.287 x | 6.573 x | 6.776 x | 6.747 x | 7.47 x | 7.538 x |
| Free Cash Flow 1 | -135,391 | -23,544 | 96,277 | -5,814 | -122,356 | -61,877 |
| ROE (net income / shareholders' equity) | 8.74% | 3.37% | 1.21% | 4.11% | 9.87% | 12.3% |
| ROA (Net income/ Total Assets) | 3.68% | 3.33% | 2.75% | 3.03% | 3.54% | 3.81% |
| Assets 1 | 528,678 | 236,509 | 101,850 | 315,903 | 690,665 | 868,257 |
| Book Value Per Share 2 | 182.0 | 185.0 | 180.0 | 186.0 | 203.0 | 218.0 |
| Cash Flow per Share 2 | 29.60 | 23.10 | 37.70 | 37.20 | 20.10 | 46.20 |
| Capex 1 | 6,355 | 10,817 | 3,813 | 4,473 | 5,359 | 19,933 |
| Capex / Sales | 0.27% | 0.4% | 0.14% | 0.15% | 0.17% | 0.59% |
| Announcement Date | 18/03/19 | 30/03/20 | 31/05/21 | 31/03/22 | 04/04/23 | 28/03/24 |
1IDR in Million2IDR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -20.25% | 9.79M | |
| +41.96% | 630B | |
| -7.15% | 350B | |
| +18.77% | 328B | |
| +8.79% | 298B | |
| +18.02% | 246B | |
| +1.27% | 225B | |
| +11.95% | 218B | |
| +3.68% | 160B | |
| -4.38% | 156B |
- Stock Market
- Equities
- SDPC Stock
- Financials PT Millennium Pharmacon International Tbk